Israel's fastest growing startup ecosystem
The more than 100 high-tech companies involved in R&D concentrated in Yokneam export nearly $6 billion of technology and high tech products a year. "National Priority Area A" investment grants and tax benefits, lower housing prices and its village-like surroundings make it easier for companies to grow from startup to mature companies in Yokneam without losing key personnel.
While Tel-Aviv is more oriented to the young entrepreneurs who have not yet settled down, Yokneam attracts the seasoned entrepreneurs and high tech professionals needed for longer term R&D in industries like: Medical Devices, Pharmacology, Surgical Equipment, Water Technology, Homeland Security, Electro-Optics and Image Recognition, Industrial Tools and Processes, Semiconductors and Network Infrastructure.
Yokneam's proximity to the Technion and University of Haifa, combined with the natural laboratory of its surroundings has made it a magnet for the development of new and hybrid technologies in sectors like: Internet of Things (IoT), Business Management, eCommerce and as a Service (_aaS) technologies, and technologies that can't yet be classified.
In addition to the "National Priority A Area" investment grants and tax benefits of up to 20%, funding for startups is readily available in Yokneam.
Jack Lazar, Jon Olson and Greg Waters will replace Dov Baharav, Shai Cohen and Tom Riordan on the Board of Directors of Mellanox as part of the agreement between Mellanox and Starboard. The agreement also calls for operating performance thresholds for FY2018 and FY2019 that will determine whether Starboard will have the right to appoint a direct representative to the Board.
Mike McGurl of MCRA met with representatives from a number of medical device companies in Yokneam to give an FDA/U.S. General Regulatory Overview and answer questions for local companies.
GenomeWeb recently reported that Curewize Health in Yokneam aims to have a test for guiding treatment decisions in acute lymphoblastic leukemia patients on the European market by the beginning of next year. Curewize claims that the clinical test trial that it completed on patients from a European National Registry Study provides information related to the possibility of relapse in patients based on the presence or absence of microRNA biomarkers. The test stratifies the patients into risk-based treatment groups. , identifying patients that are at a high risk of relapse before starting treatment.
Senior Sales Director
Mechanical engineer - מהנדס מכונות
Shlomi Cohen, Lumenis CFO will speak on “Designing Strategy for Value Creation & Better Technology for Better Patient Care” followed by a panel discussion. Also, Opportunities, Open Positions, Networking and more…